In NSCLCs [49], SIT downregulated the expression of cyclin D-CDK4 and cyclin D-CDK2, whereas in cancers of the oral cavity and pharynx [84], SIT inhibited the expression of cyclin B. Accordingly, SIT blocked the cell cycle progression of these cancer cells at the G0/G1 and G2/M phases, respectively. The gene discussed is CDK2; the disease is cancer.